Page 1315 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

6 References

157. Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood correcting laboratory parameters of haemostasis in critically ill
products transfused affects mortality in patients receiving patients. Br J Haematol. April 2004;125(1):69-73.
massive transfusions at a combat support hospital. J Trauma. 166. Dara SI, Rana R, Afessa B, Moore SB, Gajic O. Fresh frozen
October 2007;63(4):805-813. plasma transfusion in critically ill medical patients with coagu-
158. Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and lopathy. Crit Care Med. November 2005;33(11):2667-2671.
platelet to red blood cell ratios improves outcome in 466 mas- 167. Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-
sively transfused civilian trauma patients. Ann Surg. September frozen plasma clinically effective? An update of a systematic
2008;248(3):447-458. review of randomized controlled trials. Transfusion. August
159. CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects 2012;52(8):1673-1686.
of tranexamic acid on death, vascular occlusive events, and 168. Khan H, Belsher J, Yilmaz M, et al. Fresh-frozen plasma
blood transfusion in trauma patients with significant haem- and platelet transfusions are associated with development of
orrhage (CRASH-2): a randomised, placebo-controlled trial. acute lung injury in critically ill medical patients. Chest. May
Lancet. July 3, 2010;376(9734):23-32. 2007;131(5):1308-1314.
160. Vavricka SR, Walter RB, Irani S, Halter J, Schanz U. Safety of 169. Yank V, Stafford RS. Safety of recombinant activated factor
lumbar puncture for adults with acute leukemia and restric- VII in randomized clinical trials. N Engl J Med. February 10,
tive prophylactic platelet transfusion. Ann Hematol. September 2011;364(6):575; author reply 575-576.
2003;82(9):570-573.
161. Zeidler K, Arn K, Senn O, Schanz U, Stussi G. Optimal prepro- 170. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in sur-
gery and other indications. Drugs. June 1999;57(6):1005-1032.
cedural platelet transfusion threshold for central venous cath-
eter insertions in patients with thrombocytopenia. Transfusion. 171. Mumtaz H, Williams V, Hauer-Jensen M, et al. Central venous
November 2011;51(11):2269-2276. catheter placement in patients with disorders of hemostasis. Am
162. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet J Surg. December 2000;180(6):503-505; discussion 506.
transfusion for prevention of bleeding in patients with haemato- 172. Doerfler ME, Kaufman B, Goldenberg AS. Central venous cath-
logical disorders after chemotherapy and stem cell transplanta- eter placement in patients with disorders of hemostasis. Chest.
tion. Cochrane Database Syst Rev. 2012;5:CD004269. July 1996;110(1):185-188.
163. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis 173. Foster PF, Moore LR, Sankary HN, Hart ME, Ashmann MK,
platelet-transfusion strategy for hematologic cancers. N Engl J Williams JW. Central venous catheterization in patients with
Med. May 9 2013;368(19):1771-1780. coagulopathy. Arch Surg. March 1992;127(3):273-275.
164. Lundberg GD. Practice parameter for the use of fresh- frozen 174. McVay PA, Toy PT. Lack of increased bleeding after paracentesis
plasma, cyroprecipitate, and platelets. JAMA. March 9, and thoracentesis in patients with mild coagulation abnormali-
1994;271(10):777-781. ties. Transfusion. February 1991;31(2):164-171.
165. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. 175. Aster RH, Bougie DW. Drug-induced immune thrombocytope-
Efficacy of standard dose and 30 ml/kg fresh frozen plasma in nia. N Engl J Med. August 9, 2007;357(6):580-587.

Section07-O-ref.indd 6 1/21/2015 11:26:48 AM